Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit- containing N-methyl-D-aspartate receptors

Experimental Neurology

Volumn 163, Issue 1, 2000, Pages 239-243

  Steece Collier, Kathy ^a   Chambers, Leslie K ^b   Jaw Tsai, Sarah S ^b   Menniti, Frank S ^b   Greenamyre, J Timothy ^c  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b PFIZER INC   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Catalepsy; Haloperidol; Monkey; MPTP; NMDA; Parkinson's disease

Indexed keywords

DOPAMINE; HALOPERIDOL; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TRAXOPRODIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 0034067617     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2000.7374     Document Type: Article

References (26)

1. Albin R. L., Young A. B., Penney J. B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;365-375.
2. Blanchet P. J., Konitsiotis S., Whittemore E. R., Zhou Z. L., Woodward R. M., Chase T. N. Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 290:1999;1034-1040.
3. Calabresi P., Mercuri N. B., Sancesario G., Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Brain. 116:1993;433-452.
4. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
5. Chenard B. L., Bordner J., Butler T. W., Chambers L. K., Collins M. A., De Costa D. L., Ducat M. F., Dumont M. L., Fox C. B., Mena E. E. (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: A potent new neuroprotectant which blocks N-methyl-d-aspartate responses. J. Med. Chem. 38:1995;3138-3145.
6. Chenard B. L., Menniti F. S. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr. Pharm. Des. 5:1999;381-404.
7. DeLong M. R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13:1990;281-285.
8. Dingledine R., Borges K., Bowie D., Traynelis S. F. The glutamate receptor ion channels. Pharmacol. Rev. 51:1999;7-61.
9. Greenamyre J. T. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J. Neural Transm. 91:1993;255-269.
10. Greenamyre J. T., Eller R. V., Zhang Z., Ovadia A., Kurlan R., Gash D. M. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol. 35:1994;655-661.
11. Kew J. N. C., Trube G., Kemp J. A. A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J. Physiol. 497:1996;761-772.
12. Klockgether T. L. Turski, Honoré T., Zhang Z., Gash D. M., Kurlan R., Greenamyre J. T. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30:1991;717-723.
13. Kurlan R., Kim M. H., Gash D. M. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey Parkinsonism. Mov. Disord. 6:1991;111-118.
14. Löschmann P.-A., Lange K. W., Kunow M., Rettig K.-J., Jahnig P., Honoré T., Turski L., Wachtel H., Jenner P., Marsden C. D. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with l-Dopa in models of Parkinson's disease. J. Neural. Transm. Parkinson's Dis. Sect. 3:1991;203-213.
15. Menniti F., Chenard B., Collins M., Ducat M., Shalaby I., White F. CP-101,606, a potent neuroprotectant selective for forebrain neurons. Eur. J. Pharmacol. 331:1997;117-126.
16. Menniti F. S., Shah A. K., Williams S. A., Wilner K. D., White W. F. CP-101,606: An NR2B-selective NMDA receptor antagonist. CNS Drug Rev. 4:1998;307-322.
17. Mott D. D., Doherty J. J., Zhang S., Washburn M. S., Fendley M. J., Lyuboslavsky P., Traynelis S. F., Dingledine R. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat. Neurosci. 1:1998;659-667.
18. Nash J. E., Hill M. P., Brotchie J. M. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp. Neurol. 155:1999;42-48.
19. Parent A., Hazrati L.-N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res. Rev. 20:1995;128-154.
20. Neurology. 52:1999;A262.
21. Rogawski M. A. Therapeutic potential of excitatory amino acid antagonists: Channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14:1993;325-331.
22. Standaert D. G., Testa C. M., Young A. B., Penney J. B. Jr. Organization of N-methyl-d-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J. Comp. Neurol. 343:1994;1-16.
23. Starr M. S. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse. 19:1995;264-293.
24. Taniguchi K., Shinjo K., Mizutani M., Shimada K., Ishikawa T., Menniti F. S., Nagahisa A. Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. Br. J. Pharmacol. 122:1997;809-812.
25. Tossman U., Segovia J., Ungerstedt U. Extracellular levels of amino acids in striatum and globus pallidus of 6-hydroxydopamine-lesioned rats measured with microdialysis. Acta Physiol. Scand. 127:1986;547-551.
26. Wichmann T., DeLong M. R. Functional and pathophysiological models of the basal ganglia. Curr. Op. Neurobiol. 6:1996;751-758.